Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regencell Bioscience HoldingsRGC -1.67%30 Equity-to-Asset is 0.41 as of Dec. 2025, which is 54% below its 10-year median of 0.90. GuruFocus rates RGC with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Regencell Bioscience Holdings ranks worse than 73.76% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Regencell Bioscience Holdings Equity-to-Asset Related Terms
Regencell Bioscience Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGC vs SUPN, BCRX, PBH: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regencell Bioscience Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Regencell Bioscience Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regencell Bioscience Holdings (RGC) has a Equity-to-Asset of 0.41 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Regencell Bioscience Holdings and its competitors. This is 54% below median its historical median of 0.90. According to the industry distribution chart, Regencell Bioscience Holdings ranks #742 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 73.8%.
Is Regencell Bioscience Holdings' Equity-to-Asset too high?
Regencell Bioscience Holdings' current Equity-to-Asset of 0.41 is 54% below median its 10-year median of 0.90. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Regencell Bioscience Holdings' value of 0.41 is 32.8% below this industry median. Based on the distribution chart, Regencell Bioscience Holdings ranks #742 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Regencell Bioscience Holdings has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Equity-to-Asset compare to SUPN and BCRX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #742 out of 1006 companies for Equity-to-Asset. This places Regencell Bioscience Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Regencell Bioscience Holdings' value of 0.41 is 32.8% below this benchmark. While the company's 10-year median is 0.90 vs. the industry median of 0.61, Regencell Bioscience Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regencell Bioscience Holdings's current Equity-to-Asset of 0.41 is 32.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Regencell Bioscience Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current Equity-to-Asset is 0.41, which is 54% below median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Equity-to-Asset of 0.41. The current Equity-to-Asset is 0.41, which is 54% below median its 10-year median of 0.90 and 32.8% below the Drug Manufacturers industry median of 0.61. Regencell Bioscience Holdings' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Equity-to-Asset is 0.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
30GF Score
Get the complete analysis for RGC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGC has been successfully added to your 
